 |
Quick Links |
| Information by Disease |
|
|
|
| Cancer News |
|
|
|
| Conference Coverage |
|
|
|
| AZN | $44.82 | -0.37 (-0.82%)
| | NVS | $53.13 | -0.16 (-0.3%)
| | SNY | $37.67 | -0.01 (-0.03%)
| | GSK | $41.53 | 0.06 (0.14%)
|
|
|
Ovarian Cancer
| 249553 |
Recombinant |
GlaxoSmithKline |
II |
| Actimune |
Interferon gamma-1b |
Genentech InterMune |
III |
| Alferon N Injection |
Interferon |
Interferon Sciences |
II |
| AMD-3100 |
CXCR4 antagonist |
AnorMed |
II |
| APC 8024 |
Her-2 Vaccine |
Dendreon |
I |
| Aroplatin |
Liposomal platinum |
Antigenetics |
II |
| AVE-8062 |
Angiogenesis inhibitor |
Aventis |
I/II |
| BMS 184476 |
Taxane |
Bristol-Myers Squibb |
II |
| BMS 275291 (metalloproteinase) |
Selective metallaproteinase inhibitor antiangiogenic |
Bristol-Myers Squibb |
II |
| Bryostatin 1 |
Protein kinase activator |
NCI |
II |
| Cantuzunab (HuC242-DMI) |
Mertasense MoAb |
Immunogen |
I |
| CCX2 |
|
Oncosense |
II |
| CDP 860 |
PDGF antibody |
Celltech Pharmaceuticals |
II |
| Cetuximab (Erbitux) |
Anti EGFR MoAb |
Bristol-Myers Squibb Imclone |
II |
| CI-994 |
Histone deacetylase inhibitor |
Pfizer |
II |
| E7070 |
Disulphonamide |
Eisai |
II |
| EPO906 (epothilone B) |
Microtubule stabilizing agent |
Novartis |
II |
| Epothilone |
Microtubule stabilizing agent |
Bristol-Myers Squibb |
II |
| Gemzar (gemcitabine) |
antimetabolite |
Eli Lilly |
III |
| GleevecÔ Imatinib mesylate |
Protein kinase inhibitor |
Novartis |
II |
| Globo H Vaccine |
Vaccine |
Optimer Pharmaceuticals |
I |
| HMN-214 |
Anti-microtubular agent |
Idec Pharmaceuticals |
I |
| Hycamtin (topotecan) |
Topoisomerase I inhibitor |
GlaxoSmithKline |
III |
| Incel (biricodar) |
|
Vertex Pharmaceuticals |
II |
| Irolfulven (MGI-114) |
Acylfulvene analog |
MGI Pharma |
I/II |
| LEP |
Taxane |
NeoPharm |
II |
| LGD 1550 |
|
Ligand Pharmaceuticals |
II |
| MGI114 |
Acylfulvene |
MGI |
I |
| MLN 576 |
Topoisomerase I & II inhibitor |
Millennium, Xenova |
I |
| MorAb 003 |
Humanized IgGI MoAb |
Morphotek |
FDA Submission 04-05 |
| OmintargÔ(pertuzumab) |
Monoclonal antibody |
Genentech |
II |
| OSI-211 (lurtotecan) |
Liposomal topoisomerase inhibitor |
OSI Pharmaceuticals |
II |
| O-Vax |
Vaccine |
Avax Tech |
I |
| OvaRexÒ(oregovemab) |
Monoclonal antibody |
Unither Pharmaceuticals |
II |
| Oxaliplatin |
Platinum |
Sanofi-Synthelabo |
II |
| Phenoxidiol |
Synthetic flavinoid |
Marshall Edwards Inc. |
II |
| PV701 |
New Castle Disease Virus |
WellStat Biologics |
I |
| R1549 |
Monoclonal antibody |
Roche |
III |
| SGN-15 |
Antibody-drug conjugate |
Seattle Genetics |
II completed |
| TarcevaÔ (erlotinab HCL) |
Anti-EGFR |
Genentech OSI Pharmaceuticals |
II |
| Taxotere (docetaxel) |
Taxoid |
Aventis |
II |
| Telcyta (TLK286) |
Selective apoptotic agent |
Telik |
III |
| tDDC-E1A |
Genetics |
Targeted Genetics |
I |
| ThalidomidÒ(thalidomide) |
Anti-angiogenetic |
Celgene |
II |
| Tirapazamine |
Radiosensitizer |
Sanofi-Synthelabo |
II |
| UCN-01 |
Alters phosphorylation of Akt |
NCI |
I |
| VEGF Trap |
Anti-VEGF |
Aventis |
I/II |
| XyotaxÔ |
Poyglutamate paclitaxel |
Cell Therapuetics |
II |
| Yondelis (trabecitiden) |
Marine organism Ecteinascidia turbinata |
PharmaMar Ortho Biotech |
II |
|
For more information contact us at clinicaltrials@cancerconsultants.com
 |
 View Drugs in Pipeline By Disease |
 |
|
|
|
 |
|
 |
|
|
Patient Home
Meeting Calendar
